Biotechnology

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

May 11, 2023 4:05 PM

- Dermata raised $5 million gross proceeds from a public offering in March 2023 - - Dermata submitted an End of Phase 2 meeting package to FDA in April 2023 - - FDA agreed that Dermata's chemistry, manufacturing, and control ("CMC") procedures support the initiation of Phase 3 studies of DMT310 for the treatment of acne - SAN DIEGO, CA / ACCESSWIRE / May 11, 2023 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the...

Read more

NovAccess Global Lead Scientist Published in High-Profile Medical Journal for Cancer Vaccine Advancements

May 11, 2023 9:00 AM

Report Details Promise of Adaptive Cancer Immunotherapy in Treating Highly Malignant Brain Tumors Recent Achievements for Glioblastoma/Brain Tumor Treatment to be Addressed in Upcoming Presentation at World Orphan Drug Congress CLEVELAND, OH / ACCESSWIRE / May 11, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced that Dr. Christopher Wheeler, Ph.D.,...

Read more

cGMP Manufacturing Complete for Lexaria's Upcoming U.S. Phase 1b Hypertension Clinical Trial

May 11, 2023 9:00 AM

DehydraTECH-CBD is currently unique in its evidenced superior power to reduce blood pressure over other oral CBD formulations. DehydraTECH-CBD has demonstrated exceptional safety and tolerability and a sustained decrease in blood pressure. KELOWNA, BC / ACCESSWIRE / May 11, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that batch manufacturing of...

Read more

The BWB Awards at Biotech Week Boston Returns for a Celebratory Gala September 18th, 2023

May 10, 2023 1:30 PM

BOSTON, MA / ACCESSWIRE / May 10, 2023 / The BWB Awards at Biotech Week Boston returns for a night of dinner, drinks, entertainment, and the recognition of the top individuals, companies, and organizations in the life sciences community. Since 2018, the Awards at the Biotech Week Boston festival have been bringing together the faces and names that make the Boston community the beating heart of the biotech world. Join 150+ leaders across the...

Read more

Longwood Healthcare Leaders to Convene Top Biotech and Pharmaceutical Leaders at MIT Koch Institute

May 10, 2023 7:00 AM

BOSTON, MA / ACCESSWIRE / May 10, 2023 / Longwood Fund, an early-stage life science venture firm, will convene top biopharmaceutical leaders for two days of off-the-record discussions and networking at its Spring MIT Longwood Healthcare Leaders Conference, co-hosted by Nobelist and Alnylam/Biogen Co-Founder Phillip Sharp, Ph.D., at The Koch Institute at MIT June 7-8, 2023. Longwood Healthcare Leaders The industry-leading conference focuses on a...

Read more

Pieris Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Updates

May 10, 2023 7:00 AM

COMPANY TO HOST AN INVESTOR CONFERENCE CALL TODAY, WEDNESDAY, MAY 10, 2023, AT 8:00 AM EDT Enrollment for elarekibep (PRS-060/AZD1402) Phase 2a study for asthma continues to progress with topline clinical data anticipated by mid-2024; successful safety review completed for 10 mg dose cohort PRS-220, inhaled Anticalin protein for idiopathic pulmonary fibrosis (IPF), continues in Phase 1 study with topline results expected H2 2023 PRS-400, inhaled...

Read more

Lifeloc Reports First Quarter 2023 Results

May 9, 2023 4:52 PM

WHEAT RIDGE, CO / ACCESSWIRE / May 9, 2023 / Lifeloc Technologies, Inc. (OTC PINK:LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the first quarter ended March 31, 2023. First Quarter Financial Highlights Lifeloc posted quarterly net revenue of $2.165 million resulting in a quarterly net loss of $(54) thousand, or $(0.02) per diluted share. These results...

Read more

Scailyte Announces Jan Lichtenberg, CEO at inSphero, as a Member of the Board of Directors

May 9, 2023 3:00 PM

BASEL, SWITZERLAND / ACCESSWIRE / May 9, 2023 / Scailyte, a biomarker discovery company leveraging single-cell omics and artificial intelligence, is proud to announce the appointment of Jan Lichtenberg to its Board of Directors. Scailyte announces Jan Lichtenberg, CEO at InSphero, as a member of the Board of Directors Scailyte announces Jan Lichtenberg, CEO at InSphero, as a member of the Board of Directors Jan Lichtenberg, Ph.D., is Co-Founder...

Read more

L-Nutra Launches First-of-Its Kind Longevity Nutrition Product Line Called 'ProLon EveryDay'

May 9, 2023 9:00 AM

First product to the market from the 'ProLon EveryDay' product line is the L-Spread, rich in Longevity Nuts sourced from Italy's Longevity Area and formulated based on the Longevity Diet by Dr. Valter Longo. LOS ANGELES, CA / ACCESSWIRE / May 9, 2023 / L-Nutra Inc., the world's leading nutrition technology company pioneering the discovery and commercialization of novel nutrition products that impact both the body's metabolism and cellular...

Read more

Nascent Biotech to Present Phase I Clinical Data at American Society of Clinical Oncology Annual Meeting

May 9, 2023 8:00 AM

NORTH PALM BEACH, FL / ACCESSWIRE / May 9, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company whose business is focused in therapeutic monoclonal antibody space, announced today that the Company has been selected for a poster presentation at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting held in Chicago on June 2-6, 2023. The poster...

Read more

Celcuity Inc. Schedules Release of First Quarter 2023 Financial Results and Webcast/Conference Call

May 8, 2023 5:30 PM

MINNEAPOLIS, MN / ACCESSWIRE / May 8, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that it will release its financial results for the first quarter 2023 after the stock market close on Monday, May 15, 2023. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate...

Read more

Applied Energetics Announces Appointment of Dr. Stephen W. McCahon, as Chief Science Officer

May 8, 2023 9:55 AM

Dr. McCahon, co-founder of the Company, brings more than three decades of experience as a scientific researcher, technology developer, and pioneer innovating and translating optical technology to applications spanning the directed energy spectrum. TUCSON, AZ / ACCESSWIRE / May 8, 2023 / Applied Energetics, Inc. (OTCQB:AERG), a leader in the advancement of ultrashort pulse laser (USPLTM), announced today that Dr. Stephen W. McCahon, age 63, has...

Read more

Celcuity to Present Updated Results for Treatment-Naïve Patients from Phase 1b Study of Gedatolisib at the 2023 ESMO Breast Cancer Annual Congress

May 8, 2023 8:00 AM

MINNEAPOLIS, MN / ACCESSWIRE / May 8, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced publication of an abstract reporting updated results for treatment-naïve patients from the Phase 1b study of gedatolisib, a pan-PI3K/mTOR inhibitor, in combination with palbociclib and letrozole in women with HR+/HER2- advanced breast cancer (ABC). A poster...

Read more

Alia Therapeutics names Letizia Goretti as Chief Executive Officer

May 5, 2023 4:00 AM

MILAN, ITALY / ACCESSWIRE / May 5, 2023 / Alia Therapeutics, a Trento-based start-up specializing in innovative treatments for rare genetic diseases through next-generation gene editing technology, announced the appointment of Letizia Goretti as Chief Executive Officer (CEO) and Board Director, effective immediately. Letizia, who is joining Alia from Johnson & Johnson, has more than 25 years of international experience in life sciences. She...

Read more

Chi Botanic Inc. Awarded Competitive USDA SBIR Phase I Grant for Plant Cell-Cultured Vanilla

May 4, 2023 9:00 AM

Small Business Innovative Research Program Provides $175,000 in Funding for Chi Botanic's Sustainable Vanilla Technology ALAMEDA, CA / ACCESSWIRE / May 4, 2023 / ChiBotanic Inc. is pleased to announce that its research and commercialization project for a new cell-cultured Vanilla 2.0 technology for a plant-based full-spectrum natural vanilla flavor has been awarded a highly competitive Small Business Innovative Research (SBIR) Phase I Award of...

Read more

Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and Development

May 4, 2023 8:35 AM

Dr. Bissonnette brings over 25 years in small molecule and biotherapeutic drug discovery and development, oncology and inflammation research and regulatory expertise FRAMINGHAM, MA / ACCESSWIRE / May 4, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced it has engaged Reid P....

Read more

Pieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibep (PRS-060/AZD1402)

May 4, 2023 8:00 AM

BOSTON, MA / ACCESSWIRE / May 4, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced the successful safety review of the 10 mg dry powder dose safety cohort from the ongoing multi-center, placebo-controlled phase 2a study of dry powder...

Read more

Biomed Industries, Inc. Offers to Acquire Quince Therapeutics, Inc.

May 3, 2023 9:00 AM

Offer is at $2.50 per share, or 60% premium to yesterday's closing price The offer consists of $1.55 in cash per share and $1.00 in shares of Biomed Industries, Inc. SAN JOSE, CA / ACCESSWIRE / May 3, 2023 / Earlier today Biomed Industries, Inc. issued a letter to the Board of Directors of Quince Therapeutics, Inc. (NASDAQ:QNCX). The letter described a proposal to acquire all the company's common stock for $2.50 pershare in cash and stock of...

Read more

Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison

May 3, 2023 8:35 AM

Mr. Cullison brings over 20 years of experience in the pharmaceutical industry with a broad range of expertise across business development and strategic planning FRAMINGHAM, MA / ACCESSWIRE / May 3, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced it has engaged Scott N. Cullison...

Read more

Longwood Fund Closes $180 Million Fund to Create and Invest in Early-Stage Biotechnology Companies

May 3, 2023 7:00 AM

BOSTON, MA / ACCESSWIRE / May 3, 2023 / Longwood Fund, a venture capital firm dedicated to creating and investing in science-based companies that develop novel solutions to treat important unmet medical needs, today announced the closing of its sixth fund with $180 million committed to the fund and related vehicles, representing the firm's largest fund to date. Longwood Fund General Partners Christoph Westphal and David Steinberg "We are...

Read more